Evidence map›Paper›PMID 36874509›Full record

ArticleKidney medicine2023

Kidney Cell Cycle Arrest and Cardiac Biomarkers and Acute Kidney Injury Following Angiography: The Prevention of Serious Adverse Events Following Angiography (PRESERVE) Study.

Raghavan Murugan, Monique Y Boudreaux-Kelly, John A Kellum, Paul M Palevsky, Steven Weisbord, Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON) Study Investigators

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Kidney medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03004950 (Biomarker Effectiveness Analysis in Contrast Nephropathy), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03004950 completednot on this map

Biomarker Effectiveness Analysis in Contrast Nephropathy

TypeobservationalSponsorUniversity of PittsburghRan2016 to 2023Enrolled922ConditionsAcute Renal Failure, Kidney Diseases, Chronic Kidney Disease, Coronary (Artery)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Raghavan MuruganThe Program for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Monique Y Boudreaux-KellyOffice of Research and Development, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA.
John A KellumThe Program for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Paul M PalevskyThe Program for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Steven WeisbordRenal and Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON) Study Investigators
University of Pittsburgh · USVA Pittsburgh Healthcare System · US

Funding

Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)R01DK106256 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MURUGAN, RAGHAVAN · 2016 to 2020
$1.1M
Biomarker Collection and Analysis in the PRESERVE Trial CohortR01DK098214 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PALEVSKY, PAUL M, PARIKH, CHIRAG R · 2013 to 2013
$773k
NIDDK NIH HHS R01 DK098214NIDDK NIH HHS R01 DK106256
6 · The paper itself

Abstract

Rationale & Objective: Recent studies in patients with chronic kidney disease (CKD) indicate that most cases of contrast-associated acute kidney injury (CA-AKI) are mild and are not associated with elevation in kidney injury biomarkers. We used highly sensitive kidney cell cycle arrest and cardiac biomarkers to assess the risk of CA-AKI and major adverse kidney events in patients with CKD undergoing angiography. Study Design: A retrospective study. Setting & Participants: A subset of 922 participants from the Prevention of Serious Adverse Events following Angiography trial. Predictors: Pre- and postangiography urinary tissue inhibitor of matrix metalloproteinase [TIMP]-2 and insulin growth factor binding protein [IGFBP]-7 were measured in 742 subjects, and plasma β natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hs-CRP), and serum troponin (Tn) in 854 participants using samples obtained 1-2 hours before and 2-4 hours after angiography. Outcomes: CA-AKI and major adverse kidney events. Analytical Approach: We fitted logistic regression to examine association and area under the receiver operating characteristic curves for risk prediction. Results: There were no differences in postangiography urinary [TIMP-2]•[IGFBP7], plasma BNP, serum Tn, and hs-CRP concentrations among patients with and without CA-AKI and major adverse kidney events. However, higher pre- and postangiography median plasma BNP (pre: 200.0 vs 71.5, pg/mL, Limitations: Most participants were men. Conclusions: Most mild CA-AKI cases are not associated with urinary cell cycle arrest biomarker elevation. Significant elevation in preangiography cardiac biomarkers may reflect patients with more significant cardiovascular disease that may predispose to poor long-term outcomes independent of CA-AKI status.

Indexed as

angiographyBiomarkercell cycle arrestchronic kidney diseasecontrast-associated acute kidney injurymajor adverse kidney events

Identifiers

PMID36874509
PMCPMC9976574
OpenAlexW4313528758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.